Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study
The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to evaluate the efficacy, safety and tolerability of rivastigmine capsules in patients diagnosed with probable vascular dementia (VaD). METHODS: VantagE (Vascular Dementia trial studying Exelon) was a 24-week, multicentre, double-blind study. VaD patients aged 50-85 years were randomized to rivastigmine capsules (3-12 mg/day) or placebo. Efficacy assessments included global and cognitive performances, activities of daily living and neuropsychiatric symptoms. Adverse events were recorded. Additional exploratory analyses determined whether heterogeneity in pathologies and symptoms extended to differential treatment effects. TRIAL REGISTRATION: NCT00099216. RESULTS: 710 patients were randomized. Rivastigmine demonstrated superiority over placebo on three measures of cognitive performance (Vascular Dementia Assessment Scale, Alzheimer's Disease Assessment Scale cognitive subscale, Mini-Mental State Examination; all p< or = 0.05, intent-to-treat population [ITT]), but not other outcomes. Predominant adverse events were nausea and vomiting. Exploratory analyses indicated that older patients (> or =75 years old), assumed more likely to also have Alzheimer's disease (AD) pathology, demonstrated significant cognitive responses to rivastigmine and a safety profile similar to that seen in AD patients. Younger patients, assumed less likely to have concomitant AD pathology, showed no efficacy response and were associated with slight elevations of blood pressure, cerebrovascular accidents and mortality. Rivastigmine-placebo differences in patients with, versus those without, medial temporal atrophy (also suggestive of concomitant AD) showed a numerical difference similar to that seen between the older versus younger patients, but did not attain statistical significance. CONCLUSION: Consistent with trials evaluating other cholinesterase inhibitors, rivastigmine did not provide consistent efficacy in probable VaD. The efficacy apparent on cognitive outcomes was derived from effects in older patients likely to have concomitant Alzheimer pathology. This is supportive of an existing argument that the putative cholinergic deficit in VaD reflects the presence of concomitant Alzheimer pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the single trial of rivastigmine, there was a significant benefit on the cognition without significant global benefit or benefit on activities of daily living. 265”
From Vascular Cognitive Impairment (2017) · cites this paper as [265]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Scheltens, P., Leys, D., Barkhof, F., Huglo, D., Weinstein, H. C., Vermersch, P., Kuiper, M., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,784
Self-citationRivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
Self-citation
Research works printed but not linked: 8
- Heyman A, 1998, Consortium to Establish a Registry for Alzheimer's disease. Neurology, 51, 159
- Roman GC, 1993, Report of the NINDS-AIREN International Workshop. Neurology, 43, 250
- Gottfries CG, 1994, Dementia, 5, 163
- Erkinjuntti T, 2000, J Neural Transm Suppl, 59, 23
- Folstein MF, 1975, A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, 189
- Ferris SH, 1999, Alzheimer Dis Assoc Disord, 13, S140
- Corey-Bloom J, 1998, Int J Geriatr Psychopharmacol, 1, 55
- 10.1016/s1474-4422(07)70195-3 · DOI · Paper page
Cited by
Items 101–159 of 159
Лобзин, С. В., М.Г., С., & Nalkin, S. A. (2017) · HERALD of North-Western State Medical University named after I I Mechnikov · Cited by 2
Patel, A. V., & Libman, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_37 · Cited by 1
Alcohol Misuse in Older People
Rao, R., & CROME, I. B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.009 · Cited by 1
Understanding the Person with Dementia: A Clinico-Philosophical Case Discussion
Hughes, J. C., & Beatty, A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.027 · Cited by 1
Major or Mild Vascular Neurocognitive Disorder
Espiritu, A. I., Balakrishnar, K., Moradizadeh, M., Marlatt, N. E., & Burhan, A. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-47802-4_21 · Cited by 1
Utilidad de los fármacos en la demencia
Moneo, M. J. G. (2010) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(10)70126-2 · Cited by 1
Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating
Russo, M. J., & Allegri, R. (2014) · Current Psychopharmacologye · doi:10.2174/2211556003666140702190144 · Cited by 1
Disturbi cognitivi di origine vascolare
Planton, M., Albucher, J., & Pariente, J. (2016) · EMC - Neurologia · doi:10.1016/s1634-7072(16)80384-0 · Cited by 1
Therapy of poststroke cognitive impairment
Emelin, А. Y. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-17-38-41 · Cited by 1
Pharmacological Treatment: Current Evidence for Clinical Uses of Alzheimer’s Disease Drugs
Yoon, C. W. (2020) · Stroke revisited · doi:10.1007/978-981-10-1433-8_11 · Cited by 1
Byars, J. A., & Jorge, R. E. (2020) · doi:10.1093/med/9780198713005.003.0046 · Cited by 1
Li, J., Man, Q., Wang, W., Pang, R., Liu, J., Zhang, F., & Zhang, A. (2020) · Medicine · doi:10.1097/md.0000000000022798 · Cited by 1
Clinical Topics in Old Age Psychiatry
Lilford, P., Adshead, G., & Hughes, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714 · Cited by 1
Palliative Care in Dementia: Issues and Evidence
Hughes, J. C., Jolley, D. J., Jordan, A., & Sampson, E. L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.020 · Cited by 1
Neuropharmacology of Dementias
Ransmayr, G. N. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_259 · Cited by 1
Manso-Calderón, R. (2013) · Gredos (University of Salamanca) · doi:10.14201/gredos.123009 · Cited by 1
Weglage, L. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-11023 · Cited by 1
Hemiparesis followed by dementia
Deschaintre, Y., Massoud, F., & Léger, G. C. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997433.009
Vascular Cognitive Impairment: An Overview
O'Brien, J. T. (2011)
Psychopharmacologic Treatments for Alzheimer Disease and Related Dementias
Gomoll, B. P., Watson-Sanders, B. D., & Caserta, M. T. (2013) · Psychopharm Review · doi:10.1097/01.psyphr.0000442519.29442.6a
Mental Health Laws from All UK Jurisdictions
Burrell, C., & Emmett, C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.024
Duco, L., Legendre, C., Châtellier, G., & Saint‐Jean, O. (2019) · Trends in Geriatric Healthcare · doi:10.36959/452/576
“Rivastigmine 2008 Ballard C, 2008 [55] NCT00099216 710 73 6 Cognition, Clinician’s clinical impression Yes Great Britain, United States, Netherlands, Switzerland Yes Mild to moderate AE (include SAE): 27% rivastigmine group, 5% placebo group SAE : 15.”
BackgroundClinical Reasoning: A 76-Year-Old Woman Presented with Sudden Memory Impairment
Lee, S. M., & Moon, S. Y. (2020) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2020.2.15
Epidemiology and Mental Health in Old Age
Lilford, P., & Hughes, J. C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.004
Neuropharmacology of Dementias
Ransmayr, G. N. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_259-1
Mental Health in Parkinson’s Disease
Jones, S., Torsney, K., Scourfield, L., Berryman, K., & Henderson, E. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.011
Mitchell, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.014
Current awareness: Pharmacoepidemiology and drug safety
(2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1646
Residence Capacity: Its Nature and Assessment
Hughes, J. C., Poole, M., Louw, S., Greener, H., & Emmett, C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.026
Lilford, P. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.028
Series, H. G., & Esiri, M. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.005
Hughes, J. C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.003
Supporting Self-Management in Early Dementia: A Contribution Towards ‘Living Well’?
Cheffey, J., Hill, L., & Roberts, G. A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.017
Deprivation of Liberty: Where Are We Now?
Brindle, N., & Walsh, C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.025
Controlling the Confusion: Using Barrier Analysis in the Care Home Sector
Colgate, R., Turner, A., & Rafferty, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.023
The Home Assessment in Old Age Psychiatry: A Practical Guide
Ng, B., & Atkins, M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.012
Jefferies, K., & Agrawal, N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.006
Richards, F., & Curtice, M. J. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.008
Drug Misuse in Older People: Old Problems and New Challenges
Wagle, A. C., & Badrakalimuthu, V. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.010
Meagher, D. J., O'Connell, H. P., Cullen, W., & Adamis, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.022
Gupta, S., Fiertag, O., Thanulingam, T., Strange, B. A., & Warner, J. P. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.007
Driving in Dementia: A Clinician’s Guide
Wilson, S., & Pinner, G. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.013
Hughes, J. C., & Lilford, P. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.001
Biomarkers and the Diagnosis of Preclinical Alzheimer’s Disease
Lilford, P., & Hughes, J. C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.015
Hughes, J. C., & Lilford, P. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.002
To Scan or Not to Scan: Neuroimaging in Mild Cognitive Impairment and Dementia
Sullivan, V., Majumdar, B., Richman, A. V., & Vinjamuri, S. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.016
Đukić, N., Nešković, M., Ševković, M., & Radak, Đ. (2016) · Medicinska istrazivanja · doi:10.5937/medist1602023q
Hughes, J. C., & Lilford, P. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.029
Troubles cognitifs d’origine vasculaire
Planton, M., Albucher, J., & Pariente, J. (2016) · HAL
Atherosclerosis: The 21st Century Epidemic
(2011) · Libreria Editrice Vaticana eBooks · doi:10.65398/agvh4012
Campos, C. M. C. G. Q., Maia, A. P. C., Albino, I. R. M., dos Santos, J. V. L., Vasconcelos, L. R. D. S., Rangel, R. F. B. C., & Horta, W. G. (2025) · Brazilian Journal of One Health · doi:10.70164/bjoh.v2i6.241
Milosevich, E. T. (2022) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qoy61ngz6
fk, U. (n.d.) · Document Repository (Universitas Andalas)
Enhancing Cognition by using Low-cost In-home Portable Sleep Equipment: A Feasibility Study
Colelli, D. R. (2019) · TSpace (University of Toronto)
VASCULAR COGNITIVE IMPAIRMENT: RISK FACTORS, PREVENTION AND TREATMENT
Szarek, R., Kulka, K., Król, W., Kafara, Z., Kowalczyk, D., Lechowska, Z., Kafara, A., Koronczok-Matusiak, J., Michta, K., Strzałkowska, B., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5302
Gong, L., Lang, H., & Yang, J. (2026) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2026.100563
“…convincing disease modification: donepezil evidence includes multiple trials and a Cochrane review [50 – 53], rivastigmine has been tested in probable VaD [54], memantine has randomized trial evidence [55], and broader meta-analytic syntheses report small or uncertain clinical effects [56 – 57].”
Metadata
- Authors
- Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R.
- Affiliations
- King's College London (GB)
- Westmoreland Neurology, Greensburg, Pennsylvania, USA
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Novartis (United States) (US)
- Department of Neurology, Radiology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
- Novartis (Switzerland) (CH)
- Corresponding author
- Ballard, C.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-07-30
- Volume
- 24
- Issue
- 9
- Pages
- 2561-2574
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2150693120
- Cited by
- 147
- References
- 57
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 41 · 2019: 6 · 2018: 4 · 2017: 12 · 2016: 11 · 2015: 9 · 2014: 5 · 2013: 9 · 2012: 5
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- rivastigmine, vascular dementia, cholinesterase inhibitors, cognitive performance, Alzheimer's disease pathology, medial temporal lobe atrophy, age differences in treatment response, adverse events, neuropsychiatric symptoms, activities of daily living
- MeSH terms
- Rivastigmine, Administration, Oral, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Prospective Studies, Dementia, Vascular, Treatment Outcome, Neuroprotective Agents, Phenylcarbamates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.